HERBALIFE LTD. (HLF): what the price requires
The current priced-in claim for HERBALIFE LTD. (HLF) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/HLF
Headline
| Field | Value |
|---|---|
| Ticker | HLF |
| Company | HERBALIFE LTD. |
| Current price | $13.06/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 6.0% |
| Operating margin today | 10.2% |
| Margin compression implied | -4.2pp |
| Multiple paid | 6x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.
Solve inputs: computed at a 9.2% cost of capital with 4% terminal growth over a 5-year stage.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.46σ |
| cohort percentile (of 113 peers) | 2 |
| implied end-window share | 0% |
Valuation X-Ray
The price is supported by earnings-power and relative-multiple value. A value/asset-supported name, not a pure growth bet.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | — | 0 | — |
| Earnings | 0.61x | 3 | justifies |
| Relative | 0.37x | 2 | justifies |
| Growth | — | 0 | — |
Families that justify the price: Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.5%); the inversion above states its own rate.
Per-Model Detail (n=5)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | — | — | no | — |
| DCF Exit Multiple | Growth | $24.77 | 0.53x | no | Exit EV/EBITDA: 4.0x / 6.0x / 8.0x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $30.40 | 0.43x | yes | P/E 13.16x (blended: static sector reference 18x + trailing (TTM) 6x), scenarios: 11.0x / 13.2x / 15.3x (bear / base = reference held flat / bull), EV/EBITDA 9.6x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | — | — | no | — |
| Two-Stage Excess Return | Asset | — | — | no | — |
| Discounted Future Market Cap | Growth | $8.76 | 1.49x | no | Rev $5.1B, growth 4% (input: historical growth; tapered), Terminal P/S: 0.2x / 0.3x / 0.3x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $27.36 | 0.48x | no | EPS $2.28, growth 2% (input: historical EPS growth), PEG=2.95 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $47.20 | 0.28x | no | Normalized EBIT (5y avg op income, one-time charges added back) $0.50B × (1−33%) / WACC 4.5% → EPV (no growth) |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | $42.18 | 0.31x | yes | EBITDA $0.53B × sector EV/EBITDA 12.0x |
| FCF Yield | Earnings | $21.24 | 0.61x | yes | FCF $373.9M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $16.94 | 0.77x | yes | SBC-adj FCF $0.33B (FCF $0.37B − SBC $0.04B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $73.57 | 0.18x | yes | EPS $2.28 × (8.5 + 2×15.0%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $118.38 | 0.11x | no | Revenue $5.13B × sector P/S 2.5x |
| PEG Fair Value | Relative | $85.50 | 0.15x | no | EPS $2.28 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x |
| Earnings Yield | Earnings | $24.65 | 0.53x | no | EPS $2.28 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $1.5b |
| Net debt / NOPAT (after-tax) | 4.44x |
| Net debt / operating income (pre-tax) | 2.97x |
| Interest coverage | 2.6x |
| Share count CAGR (dilution) | 1.6% |
| Burning cash | no |
Bullet Takeaways
- Herbalife sells nutrition products through a network of independent distributors rather than retail shelves, competing for recruits against other direct sellers the 10-K names directly: Medifast, Inc., Nu Skin Enterprises, Inc., USANA Health Sciences, Inc.; the health of that recruiting funnel, not shelf space, is the business.
- The biggest risk is the balance sheet: net debt near $1.5 billion against trailing operating income that covers interest only about 2.4 times, so the senior secured refinancing the company is working through is the load-bearing event for equity holders.
- Watch new-distributor trends and the refinancing terms; after twelve straight quarters of year-over-year declines in new distributors, Q1 2026 showed new-distributor growth up 13% on a two-year stack, an early sign the recruiting funnel may be stabilizing.
Bull Case
What a standard valuation model misses about Herbalife is that its real asset is not on the balance sheet. The buildings and inventory matter little; the value is a global distribution network of independent sellers and the brand loyalty that keeps customers reordering. The company describes its own strategy as driving more frequent interactions between and amongst Members and their customers, which we believe enhances the customer's experience and further builds customer loyalty. A model that prices the tangible assets sees a cheap, leveraged consumer company; what it cannot easily price is a recruiting-and-reorder machine that, when it works, generates cash with very little capital behind it.
The most recent quarter suggests the machine may be turning back on. Q1 2026 net sales were $1.3 billion, up 7.8% year over year and ahead of guidance, with earnings of $0.64 per share beating the $0.58 estimate. More important than the headline beat is the funnel underneath it: after twelve consecutive quarters of declining new-distributor counts, new-distributor growth rose 13% on a two-year stack basis. For a direct seller, the new-distributor number is the leading indicator the way same-store traffic is for a retailer. A turn there, if it holds, is what converts a low multiple into a re-rating.
The price is the bull's other ally. At roughly $12 (June 27, 2026) a share the stock trades around 6 times operating income, a level so low that the value is supported even if operating profit were to shrink a few percent a year rather than grow. Trailing operating income near $500 million is real cash, and the company raised its full-year 2026 constant-currency net sales and adjusted EBITDA guidance midpoints. The bull case does not require Herbalife to grow quickly; it requires the business to stabilize while the equity trades at a price that already assumes decline. If the distributor turn is genuine, the gap between a stabilizing business and a price that assumes erosion is the opportunity.
Bear Case
The valuation methods disagree on Herbalife, and the conservative ones are likely the more honest read. Only the earnings-power and peer-multiple lenses support the price; the asset-based view barely registers, because a direct-selling company has little tangible value to anchor on. That should give a value buyer pause: the cheap multiple exists not because the market overlooked a bargain but because the cash flows are levered and the business model carries tail risk that a 6-times multiple is trying to discount.
The leverage is the first concrete worry. Net debt sits near $1.5 billion against trailing operating income that covers interest only about 2.4 times, and net debt runs more than three times operating income. Quarterly interest expense of roughly $49.5 million is a fixed claim on cash before equity holders see anything. The company is actively working a senior secured refinancing, and the terms it lands will set the cost of capital for years; a refinancing into a higher coupon narrows the cash that funds the dividend, the buyback, and reinvestment in the very distributor incentives the growth story depends on.
The second worry is structural and the filing names it. Herbalife's classification of its sellers is not settled everywhere: the 10-K warns there can be no assurance that other jurisdictions or authorities will provide such an exemption or that judicial or regulatory authorities will not assert interpretations that would mandate that we change our classification, and that any legal or regulatory impact to our Members' ability to conduct their business could negatively impact sales. A direct-selling model lives or dies on the recruiting funnel and on its right to operate it; a single adverse regulatory interpretation in a large market can impair both at once. The twelve-quarter decline in new distributors that only just reversed shows how quickly the funnel can run the wrong way. The bear case is not that Herbalife disappears; it is that a levered business with regulatory exposure and a fragile recruiting engine is cheap for reasons the conservative methods can see and the optimistic ones explain away.
Valuation
Herbalife trades around 6 times operating income, which is the whole valuation story in one number. A multiple that low is not pricing growth; it is pricing decline. The inversion makes the point as a bound rather than a target: the price sits below what even a 5%-a-year decline in operating profit would warrant. In plain terms, an investor is being asked to believe only that the business does not fall apart, not that it improves.
The families of method split in a way that fits a levered, asset-light consumer name. Earnings-power and peer-multiple approaches support the current price; the asset-based lens has almost nothing to grip, because the company's worth is its distributor network and brand rather than property and inventory. That is normal for direct selling, but it removes the floor a value investor usually leans on. There is no book-value cushion here; the case rests entirely on the durability of the cash flows.
Those cash flows must clear a heavy fixed charge first. Net debt near $1.5 billion produces interest coverage of only about 2.4 times, and net debt runs above three times operating income, so the equity is a residual claim behind a sizable, refinancing creditor stack. Trailing operating income near $500 million and the current operating margin around 9.7% are the cushion, and the inversion implies the price needs only about 6% to be sustained, below today's level. The valuation, then, is a balance-sheet question wearing a growth disguise: the multiple is cheap, but the cheapness is the market's price for the leverage and the regulatory tail, and the refinancing terms will decide how much of the operating cash actually reaches shareholders.
Catalysts
The Q1 2026 report, released in late April, beat on both lines: net sales of $1.3 billion, up 7.8% year over year and above guidance, with earnings of $0.64 per share against a $0.58 estimate, and the company raised its full-year 2026 constant-currency net sales and adjusted EBITDA guidance midpoints. The most thesis-relevant data point sat below the headline: after twelve consecutive quarters of year-over-year declines in new distributors, new-distributor growth rose 13% on a two-year stack basis, supported by training initiatives and the Herbalife Premier League program. For a recruiting-driven model, that turn is the metric to track across the next several prints.
The larger near-term event is financial. Herbalife provided an update on its senior secured debt refinancing plans against long-term debt holding near $2.0 billion and quarterly interest expense around $49.5 million. The terms and timing of that refinancing are the single most important catalyst for the equity: a clean refinancing at a manageable rate removes an overhang and frees cash flow, while a costly one tightens the screws on an already-levered balance sheet. Watch the refinancing announcement and the next quarter's distributor data together, because the equity case depends on the recruiting funnel stabilizing at the same time the capital structure is being reset.
Peer Cohorts (Per Segment, With Filing Citations)
Primary Reporting Segment (reported)
- BRBR (BellRing Brands, Inc.)
- FY2025 10-K: …typically higher throughout the remainder of the fiscal year as a result of stronger consumer demand in the second quarter of our fiscal year, promotional activity at key retailers and organic growth of the business. Seasonal fluctuations in our net sales and EBITDA may not be the same in the future as they have been…
- FY2025 10-K: …by our management and is qualified by, and subject to, the assumptions and the other information contained or referred to in such release and the factors described under "Cautionary Statement on Forward-Looking Statements" in our current and periodic reports filed with the SEC. Our guidance is not prepared with a…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Q1 2026 earnings release